We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Neurolentech Signs Technology Access Partnership With Kaerus Bioscience To Advance Neurodevelopmental Disorder Research

A lab worker holding a rack of centrifuge tubes.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Neurolentech, announced a technology access partnership with Kaerus Bioscience, a biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. The agreement enables Kaerus Bioscience to access Neurolentech’s NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens to drive advances in neurodevelopmental disorders research.


Built for NDD drug discovery, Neurolentech's Platform comprises a vast collection of human-derived neuronal cell lines from patients with monogenic and complex neurodevelopmental disorders. The Platform will enable Kaerus Bioscience to model the complex neural networks underlying clinical features of genetic NDDs at a cellular level, as well as to investigate the therapeutic potential of its small molecule pipeline for numerous genetic syndromes preclinically.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

The partnership marks a significant milestone in Neurolentech’s mission to advance drug discovery for NDDs, and further reinforces its NDD Drug Discovery platform as a valuable resource for both researchers and industry partners.


Fiona Nielsen, CEO of Neurolentech, said, “We are excited to collaborate with Kaerus Bioscience in advancing their programs in the field of neurodevelopmental disorders. Our platform's unique capabilities offer unparalleled insights into disease mechanisms, facilitating the development of novel therapies."


Robert Ring, CEO of Kaerus Bioscience, added, "Our partnership with Neurolentech underscores Kaerus’ commitment to leveraging cutting-edge technology and innovative platform approaches to accelerating the discovery of treatments for patients with genetic disorders of neurodevelopment.”